Talis Biomedical Corp
TLISDelisted Sep 20, 2024- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001584751
Talis Biomedical Corp was delisted on Sep 20, 2024; its insiders filed their last Form 4 on Sep 9, 2024; 18 institutions reported holding it in 13F filings for Q2 2024, worth $6.84M in total; Greenlight Capital was the only superinvestor holding it.
13F holders, Q1 2024
Institutional positions in Talis Biomedical Corp as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +1 vs. Q4 2023
- Shares held
- 792.5K
- +145.0K (+22.4%) vs. Q4 2023
- Total value
- $6.93M
- +$2.11M (+43.7%) vs. Q4 2023
- New holders
- 3
- 5 more added
- Sold out
- 2
- 3 more reduced
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TLIS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 1 | $26 |
| Q3 2024 | 2 | $460.4K |
| Q2 2024 | 18 | $6.84M |
| Q1 2024 | 18 | $6.93M |
| Q4 2023 | 18 | $5.93M |
| Q3 2023 | 19 | $4.27M |
| Q2 2023 | 22 | $5.27M |
| Q1 2023 | 22 | $5.76M |
| Q4 2022 | 27 | $5.60M |
| Q3 2022 | 29 | $8.59M |
| Q2 2022 | 35 | $12.1M |
| Q1 2022 | 45 | $23.6M |
| Q4 2021 | 47 | $70.2M |
| Q3 2021 | 38 | $119.2M |
| Q2 2021 | 43 | $184.0M |
| Q1 2021 | 45 | $269.0M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Talis Biomedical Corp; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Qube Research & Technologies Ltd | 2 | $18 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 3 | $26 | 0.00% | +1+50.0% | Added |
| Wells Fargo & Company | 13 | $114 | 0.00% | 00.0% | Unchanged |
| Larson Financial Group LLC | 14 | $123 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 120 | $1.05K | 0.00% | −7−5.5% | Reduced |
| Advisor Group Holdings, Inc. | 122 | $1.07K | 0.00% | +17+16.2% | Added |
| ADAR1 Capital Management, LLC | 300 | $2.63K | 0.00% | +300 | New |
| Morgan Stanley | 635 | $5.56K | 0.00% | +264+71.2% | Added |
| Tower Research Capital LLC (TRC) | 927 | $8.11K | 0.00% | −61−6.2% | Reduced |
| BlackRock Inc. | 4,711 | $41.2K | 0.00% | −5,721−54.8% | Reduced |
| Renaissance Technologies LLC | 10,299 | $90.0K | 0.00% | +10,299 | New |
| Geode Capital Management, LLC | 11,890 | $104.1K | 0.00% | +610+5.4% | Added |
| Prelude Capital Management, LLC | 14,928 | $130.6K | 0.01% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 17,431 | $152.5K | 0.00% | +1,860+11.9% | Added |
| Vanguard Group Inc | 31,013 | $271.4K | 0.00% | 00.0% | Unchanged |
| BML Capital Management, LLC | 42,743 | $374.0K | 0.25% | 00.0% | Unchanged |
| DME Capital Management, LPSuperinvestorGreenlight Capital | 149,052 | $1.30M | 0.06% | +149,052 | New |
| Baker Bros. Advisors LP | 508,323 | $4.45M | 0.06% | 00.0% | Unchanged |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −10,024−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −1,624−100.0% | Sold out |
| Greenlight Capital Inc | – | – | – | – | Not filed |